Dermatology Times

FEBRUARY 20, 2025

The panelist discusses how understanding the diverse manifestations of atopic dermatitis enables health care providers to develop personalized treatment approaches for optimal patient outcomes.

Dermatitis 70

Dermatitis Treatments 70

Dermatology Times

MARCH 28, 2024

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.

Dermatitis 88

Dermatitis Dermatology Treatments 88

Dermatology Times

APRIL 12, 2024

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

Dermatitis 85

Dermatitis Treatments Safety Management 85

The Dermatology Digest

JANUARY 14, 2025

TSW commonly described as extremely red and painful skin arising when cortisone cream treatment is tapered or stopped. Cortisone cream was most often cited as the triggering factor, while some cited cortisone tablets and a few cortisone-free treatments. The post What is TSW?

Social Media 74

Social Media Eczema Hospital Dermatology 74

Dermatology Times

MAY 7, 2024

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

Dermatitis 88

Dermatitis Clinic Treatments 88

The Dermatology Digest

DECEMBER 30, 2024

the Society introduced the SOCS Center for Leadership (CFL) , an educational program designed to develop leaders who will drive the dermatology field forward. Alexis and Kwatra “Seborrheic Dermatitis in Skin of Color” with Drs. The CFL offers leadership education and development through a health equity lens.

Webinar 78

Webinar Education Social Media Dermatology 78

The Dermatology Digest

DECEMBER 27, 2024

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

Dermatitis 36

Dermatitis Portfolios Pharmaceutical Innovations 36

Dermatology Times

APRIL 5, 2024

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

Dermatitis 87

Dermatitis Treatments 87

Dermatology Times

DECEMBER 20, 2023

Tapinarof is showing promise in the landscape of dermatological treatment. Adelaide Hebert, MD, FAAD, recently served as an investigator for 2 studies presented at the European Academy of Dermatology and Venereology (EADV) Congress and discussed key points with Raj Chovatiya, MD, PhD.

Treatments 73

Treatments Dermatitis Dermatology 73

The Dermatology Digest

JANUARY 22, 2024

s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. appeared first on The Dermatology Digest.

Dermatitis 78

Dermatitis Treatments Innovations Clinic 78

Dermatology Times

APRIL 12, 2024

Linda Stein-Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences.

Dermatitis 69

Dermatitis Treatments Irritation Management 69

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.

Treatments 77

Treatments Dermatitis Therapy Medical 77

Dermatology Times

DECEMBER 12, 2023

The poster was presented at the 2023 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference.

Dermatitis 74

Dermatitis Treatments 74

Dermatology Times

SEPTEMBER 19, 2023

05% for mild to moderate atopic dermatitis in children also met secondary endpoints. Roflumilast cream.05%

Dermatitis 74

Dermatitis Treatments 74

Dermatology Times

MAY 14, 2024

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

Dermatitis 74

Dermatitis Clinic Treatments 74

Dermatology Times

MAY 21, 2024

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Dermatitis 74

Dermatitis Clinic Treatments 74

Dermatology Times

FEBRUARY 17, 2025

Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.

Dermatitis 69

Dermatitis Therapy Treatments 69

Dermatology Times

JANUARY 25, 2024

Patients with moderate to severe AD gave their opinions in a survey on treatment options and their tradeoffs. Itch control topped the list of patient concerns.

Treatments 78

Treatments Dermatitis 78

Dermatology Times

DECEMBER 28, 2023

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in atopic dermatitis this year.

Dermatitis 48

Dermatitis Dermatology Treatments 48

Dermatology Times

FEBRUARY 9, 2024

A discussion among roundtable participants revolved around the importance of effective communication, the impact of prolonged use of topical steroids, and the need for trust building in recommending novel treatment options.

Treatments 78

Treatments Dermatitis 78

The Dermatology Digest

APRIL 2, 2025

A Qin-Zhu-Liang-Xue (QZLX) decoction may help improve the symptoms of atopic dermatitis (AD), according to preclinical and clinical studies. The study included a prospective, randomized trial with 131 patients, where the treatment group received QZLX decoction, and the control group received mizolastine.

Dermatitis 36

Dermatitis Networking Dermatology Ingredients 36

Dermatology Times

OCTOBER 3, 2024

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

Dermatitis 74

Dermatitis Clinic Management Treatments 74

Dermatology Times

SEPTEMBER 3, 2024

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

Treatments 74

Treatments Dermatitis 74

Dermatology Times

JANUARY 22, 2024

Zoryve was approved for the treatment of seborrheic dermatitis in patients ages 9 years and older in December.

Dermatitis 78

Dermatitis Treatments 78

First Derm

JUNE 10, 2024

Online Dermatologist Atopic Dermatitis vs. Contact Dermatitis: What’s the Difference? Atopic dermatitis (left) and contact dermatitis (right) display different symptoms. Contact Dermatitis : Triggered by external irritants or allergens, causing localized redness, blisters, and itching.

Dermatitis 45

Dermatitis Irritation Eczema Dry Skin 45

The Dermatology Digest

FEBRUARY 26, 2024

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC. some of the JAK inhibitors).

Treatments 74

Treatments Dermatitis Pharmaceutical Clinic 74

The Dermatology Digest

OCTOBER 28, 2024

Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque psoriasis in adults. organization marks the beginning of a new chapter in dermatology. The post Done Deal: Organon Completes Acquisition of Dermavant appeared first on The Dermatology Digest.

Portfolios 36

Portfolios Dermatitis Office Partnerships 36

Dermatology Times

OCTOBER 2, 2023

Check in throughout the month to learn more about the latest treatment pearls and research findings in DermIQ’s spotlight on atopic dermatitis.

Dermatitis 74

Dermatitis Treatments 74

Dermatology Times

MARCH 4, 2025

Patients often present with autoimmune comorbidities (thyroid disorders, vitiligo, atopic dermatitis) and psychological distress. Treatment difficulties involve unpredictable responses, lack of standardized protocols, and addressing both physical symptoms and psychological impact.

Clinic 36

Clinic Treatments Dermatitis 36

Dermatology Times

JANUARY 11, 2024

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

Dermatitis 74

Dermatitis Innovations Treatments 74

Dermatology Times

SEPTEMBER 30, 2023

Colleen Cotton, MD, does a deep dive on pediatric atopic dermatitis and explains the importance of timing and conversations with patients about different treatments.

Dermatitis 78

Dermatitis Treatments 78

Dermatology Times

OCTOBER 31, 2024

Egeberg discusses promising new treatments and insights from recent clinical trials, highlighting significant advancements in chronic hand eczema and atopic dermatitis care presented at the EADV 2024.

Eczema 74

Eczema Dermatitis Clinic Treatments 74

Dermatology Times

FEBRUARY 18, 2025

Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.

Dermatology 68

Dermatology Dermatitis Therapy Treatments 68

The Dermatology Digest

MAY 7, 2025

Roflumilast foam 0.3% (Zoryve, Arcutis) performed well as a once-daily monotherapy treatment for psoriasis of the scalp and body, according to new Phase 3 data in the Journal of American Medical Association (JAMA). Roflumilast foam is under review for the treatment of scalp and body psoriasis by the U.S. of those treated with vehicle.

Dermatitis 36

Dermatitis Medical Treatments Dermatology 36

Dermatology Times

JANUARY 23, 2024

A study explored the prioritization habits of both patients with atopic dermatitis and their caregivers when it comes to treatment.

Dermatitis 78

Dermatitis Management Treatments 78

The Dermatology Digest

MARCH 17, 2025

has enrolled of the first patient in a Phase 2 trial of EVO301, an injectable interleukin (IL)-18 neutralizer, in moderate-to-severe atopic dermatitis (AD). EASI, the Eczema Area and Severity Index score, isa tool used to measure the extent and severity of atopic dermatitis. Evommune, Inc.

Dermatitis 36

Dermatitis Eczema Injections Tools 36

The Dermatology Digest

DECEMBER 11, 2024

pulling the plug on ANB032, an investigational B and T lymphocyte attenuator (BTLA )agonist that did not meet the primary and secondary endpoints in an atopic dermatitis (AD) study. The most common (>5%) AEs observed were nasopharyngitis, atopic dermatitis and headache. AnaptysBio, Inc.is

Safety 36

Safety Dermatitis Therapy Dermatology 36